Dr Lal Pathlabs Share Price Alert! Should You Buy Dr Lal Pathlabs Shares For Upcoming Dividend & Bonus Issue?

Investors are once again attracted to Dr. Lal Pathlabs due to the company's upcoming dividend and bonus issue, which the Board of Directors announced on October 31, 2025, along with the Q2FY26 results. As a result, investors are starting to wonder if now is a good time to buy shares in Dr. Lal Pathlabs. Let's analyze the most recent events, share price patterns, and potential effects for shareholders of the dividend and bonus issue.

Dr Lal Pathlabs Dividend

The Board of Directors considered and approved "Declaration of 2nd Interim Dividend of INR 7/- per equity share (@ 70% on a face value of INR 10/- each) for the financial year 2025-26. The record date for the purpose of payment of Interim Dividend shall be November 7, 2025. The 2nd Interim Dividend will be dispatched/ credited within 30 days of its declaration," said Dr Lal Pathlabs in a stock exchange filing.

Dr Lal Pathlabs Bonus Shares

The Board of Directors considered and approved "Issuance of bonus equity shares in the proportion of 1:1 i.e. 1 (One) fully paid-up equity share of face value of INR 10/- each for every 1 (One) fully paid-up equity share of face value of INR 10/- each held by the Members of the Company as on the Record Date, subject to Members, statutory and regulatory approvals, as applicable. The record date for determining the entitlement of the Members of the Company to receive bonus equity shares will be announced in due course," Dr Lal Pathlabs has confirmed in a regulatory filing.

Under this bonus issue, the corporation would issue 8,37,75,510 bonus equity shares, totalling Rs 83.77 crore. According to the audited financial accounts for the year that ended on March 31, 2025, these bonus shares will be issued from the Securities Premium Account. The issued, subscribed, and paid-up capital will double from Rs 83.77 crore to Rs 167.55 crore, representing the additional bonus equity shares issued. The company's authorized capital, after bonus, stands at Rs 1,07.96 crore, divided into 10,79,60,000 equity shares of Rs 10 apiece.

The share capital structure of Dr. Lal PathLabs will change significantly after the 1:1 bonus issue. The authorized post-bonus capital will grow to Rs 2,00,00,00,000, divided into 20,00,00,000 equity shares, each worth Rs 10. As a result, the company's issued, subscribed, and paid-up capital would also increase to Rs 1,67,55,10,200, which will be divided among 16,75,51,020 equity shares with a face value of Rs 10 apiece. To effectuate this bonus issue, a total of Rs 83,77,55,100 shall be taken out of the Securities Premium Account.

Within two months from the date of approval by the Board of Directors i.e., on or before December 30, 2025 is the estimated date by which such bonus shares would be credited/ dispatched to the eligible shareholders by Dr Lal Pathlabs.

Dr Lal Pathlabs Q2 Results

The company's revenue for the first half (FH) of FY26 increased 11% to Rs 1,400 crore from Rs 1,262 crore in FY25, while its revenue for Q2 FY26 was Rs 731 crore, up 10.7% YoY. With EBITDA rising 10.8% in Q2 to Rs 224 crore and 11.8% for the half-year ending September 30, 2025 to Rs 416 crore, the firm maintained strong operational efficiency while maintaining steady margins around 30%.

With a jump in margin to 20.4%, the company's net profit improved 16.4% in Q2 to Rs 152 crore and 20% in the first half (FH) of FY26 to Rs 286 crore. As a result, EPS jumped by 16.2% in Q2 to Rs 18.1 and by 19.9% in H1FY26 to Rs 33.9, demonstrating robust profitability.

Dr Lal Pathlabs News

On October 29, 2025, Dr. Lal PathLabs Limited notified the stock exchanges that it had received an Assessment Order and Demand Notice from the Income Tax Department for FY 2017-18. The order, which was received on October 31, 2025, calls for a tax demand of Rs 2.43 crore due to specific additions and disallowances totalling Rs 2.79 crore. According to the corporation, there is no significant impact on its operations, financial standing or other activities aside from this amount. Dr. Lal PathLabs is currently reviewing the order and intends to take appropriate steps, including filing an appeal against the assessment.

Dr Lal Pathlabs Target Price

"Dr. Lal PathLabs is exhibiting steady strength after consolidating near ₹3100 support. The stock is trading above key short-term moving averages, indicating renewed buying interest. RSI is trending upward, supporting bullish momentum. A sustained move above ₹3150 could drive the price toward ₹3230 and ₹3320. Maintain a stop-loss at ₹3050 for risk control," commented Riyank Arora, technical analyst at Mehta Equities Ltd.

"The company continues to grow organically without any price hikes for last 2.5 years and is expected to remain doing so to the tune of ~11-12% YoY. This growth is primarily supported by network expansion in the core metro markets and deeper penetration in Tier 3 and Tier 4 towns with the addition of 15-20 labs each year since FY24. The company might consider price hike post Feb-26 once internal growth targets are achieved. It would then support a stronger growth in higher teens. We project a 11-12% organic top-line growth over FY26-28, and revise our margin estimates upwards for FY27/FY28 to 29%/29.5% respectively, backed by improving Swasthfit mix and integration of Suburban. Attractive valuations at -1SD, steady growth (11-12%) and margin improvement warrant an upgrade to BUY. We value DLPL at 48x PE target multiple and roll forward to Sep'27 TP of INR 3,699 (18% upside)," said Amey Chalke of JM Financial Institutional Securities.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred to as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.